Grace Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 23, 2025
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Loss and Comprehensive Loss
| Year Ended March 31, 2025 | Year Ended March 31, 2024 | |
|---|---|---|
| (Expressed in thousands, except share and per share data) | $ | $ |
| Operating expenses | ||
| Research and development expenses, net of government assistance | (9,511) | (4,683) |
| General and administrative expenses | (7,168) | (6,684) |
| Restructuring cost | — | (1,485) |
| Loss from operating activities | (16,679) | (12,852) |
| Foreign exchange (loss) gain | (17) | (16) |
| Change in fair value of derivative warrant liabilities | 3,218 | (2,728) |
| Interest and other income, net | 711 | 911 |
| Total other income, net | 3,912 | (1,833) |
| Loss before income tax benefit | (12,767) | (14,685) |
| Income tax benefit | 3,199 | 1,832 |
| Net loss and total comprehensive loss | (9,568) | (12,853) |
| Basic and diluted loss per share | (0.79) | (1.35) |
| Weighted-average number of shares outstanding | 12,087,270 | 9,529,123 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.